{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-000180","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.982500+00:00","generated_at":"2026-06-27T19:31:14.395554+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Finch Therapeutics reports preliminary cash of $133.5M as of Dec 31, 2021","bullets":["Preliminary cash and cash equivalents of approximately $133.5M as of Dec 31, 2021.","CEO Mark Smith to present at J.P. Morgan Healthcare Conference on Jan 13, 2022.","Updated corporate presentation posted on company website for investor meetings.","Year-end audit ongoing; final cash balance may differ from preliminary estimate."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-000180","json":"https://secwatch.observer/filing/0000950170-22-000180.json","markdown":"https://secwatch.observer/filing/0000950170-22-000180.md","text":"https://secwatch.observer/filing/0000950170-22-000180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022000180/0000950170-22-000180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022000180/fnch-20220110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:31:14.395554+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}